How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution

PURPOSE: Gefitinib was introduced in 2002 for treatment of non-small cell lung cancer (NSCLC); however, it is not clear whether its use in daily practice has changed the outcome of patients. The purpose of this study is to evaluate the question of how molecular understanding regarding gefitinib and...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Keam, Bhumsuk, Kim, Dong-Wan, Park, Jin Hyun, Lee, Jeong-Ok, Kim, Tae Min, Lee, Se-Hoon, Chung, Doo Hyun, Heo, Dae Seog
Format: Artigo
Jezik:Inglês
Izdano: Korean Cancer Association 2013
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3804729/
https://ncbi.nlm.nih.gov/pubmed/24155676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2013.45.3.178
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items